Glycaemic Control and Hypoglycemia in Patients With Type 2 Diabetes Switching From Twice-Daily Basal Insulin to Once-Daily Insulin Glargine 300 U/mL or Insulin Glargine 100 U/mL

Date: 
October, 2017
July 24, 2017. This post-hoc analysis of 2 large, randomized controlled trials (EDITION 1 and EDITION 2) evaluated the effect of once-daily insulin glargine 300 U/mL (Gla-300) vs glargine 100 U/mL (Gla-100) over 6 months on blood glucose and hypoglycemia in patients with type 2 diabetes switching from twice-daily insulin. Change from baseline in A1C, assessed as least-squares mean difference, was similar for both groups in both studies: (EDITION 1, -0.01%; 95% confidence interval [CI]: -0.27%-0.24%; EDITION 2, 0.16%; 95% CI: -0.25%-0.57%). In EDITION 1, hypoglycemia rates were lower at night with Gla-300 than with Gla-100; in EDITION 2, the rates were lower with Gla-300 at any time (24 hours). The authors concluded that Gla-300 was comparable to Gla-100 for glycemic control and superior for hypoglycemia. The abstract is available here.